Trial reportInternational psychogeriatrics2016
ASPREE-D: Aspirin for the prevention of depression in the elderly.
Trial report in International psychogeriatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- The risk associated with ultra-processed food intake on depressive symptoms and mental health in older adults: a target trial emulation.BMC medicine · 2025Trial
- Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.Molecular psychiatry · 2021Trial
- Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial.JAMA psychiatry · 2020Trial
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Depressive Symptoms in Older Adults.International journal of geriatric psychiatry · 2026Article
- Diet quality and depressive symptoms in older adults, assessing the effect modification by genetic predisposition and low-grade inflammation: a target trial emulation.Molecular psychiatry · 2026Article
- Genomic risk prediction for depression in a large prospective study of older adults of European descent.Molecular psychiatry · 2025Article
- Mediterranean Diet and Ultra-Processed Food Intake in Older Australian Adults-Associations with Frailty and Cardiometabolic Conditions.Nutrients · 2024Article
- Trajectories of depressive symptoms in older adults and associated health outcomes.Nature aging · 2022Article
- Baseline characteristics and age-related macular degeneration in participants of the "ASPirin in Reducing Events in the Elderly" (ASPREE)-AMD trial.Contemporary clinical trials communications · 2020Article
- Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States.International journal of geriatric psychiatry · 2019Article
- The effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder: A randomized clinical trial.Electronic physician · 2017Article
- Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults.General hospital psychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundNot only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.
methodASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.
resultsThis paper presents the rationale for the study and presents a summary of the study design.
conclusionsASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.